Comorbidities and Factors Determining Medical Expenses and Length of Stay for Admitted COVID-19 Patients in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jang, Su Yeon | - |
dc.contributor.author | Seon, Jeong-Yeon | - |
dc.contributor.author | Yoon, Seok-Jun | - |
dc.contributor.author | Park, So-Youn | - |
dc.contributor.author | Lee, Seung Heon | - |
dc.contributor.author | Oh, In-Hwan | - |
dc.date.accessioned | 2021-12-07T23:42:35Z | - |
dc.date.available | 2021-12-07T23:42:35Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2021 | - |
dc.identifier.issn | 1179-1594 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/130197 | - |
dc.description.abstract | Purpose: No previous investigations of coronavirus disease 2019 (COVID-19) have estimated medical expenses, length of stay, or factors influencing them using administrative datasets. This study aims to fill this research gap for the Republic of Korea, which has over 10,000 confirmed COVID-19 cases. Patients and Methods: Using the nationwide health insurance claims data of 7590 confirmed COVID-19 patients, we estimated average medical expenses and inpatient days per patient, and performed multivariate negative binomial, and gamma regressions to determine influencing factors for higher outcomes. Results: According to the results, COVID-19 patients with history of ICU admission, chest CT imaging, lopinavir/ritonavir and hydroxychloroquine use stayed longer in the hospital and spent more on medical expenses, and anti-hypertensive drugs were insignificantly associated with the outcomes. Female patients stayed longer in the hospital in the over 65 age group but spent less in medical expenses that the 20-39 group. In the 40-69 age group, patients with health insurance stayed longer in the hospital and spent more on medical expenses than those aged over 65 years. Comorbidities did not affect outcomes in most age groups. Conclusion: In summary, contrary to popular beliefs, medical expenses and length of hospitalization were mostly influenced by age, and not by comorbidities, anti-viral, or antihypertensive drugs. Thus, responses should focus on infection prevention and control rather than clinical countermeasures. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | DOVE MEDICAL PRESS LTD | - |
dc.subject | PREVALENCE | - |
dc.title | Comorbidities and Factors Determining Medical Expenses and Length of Stay for Admitted COVID-19 Patients in Korea | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yoon, Seok-Jun | - |
dc.identifier.doi | 10.2147/RMHP.S292538 | - |
dc.identifier.scopusid | 2-s2.0-85107179428 | - |
dc.identifier.wosid | 000655702300001 | - |
dc.identifier.bibliographicCitation | RISK MANAGEMENT AND HEALTHCARE POLICY, v.14, pp.2021 - 2033 | - |
dc.relation.isPartOf | RISK MANAGEMENT AND HEALTHCARE POLICY | - |
dc.citation.title | RISK MANAGEMENT AND HEALTHCARE POLICY | - |
dc.citation.volume | 14 | - |
dc.citation.startPage | 2021 | - |
dc.citation.endPage | 2033 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | ssci | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Health Care Sciences & Services | - |
dc.relation.journalWebOfScienceCategory | Health Care Sciences & Services | - |
dc.relation.journalWebOfScienceCategory | Health Policy & Services | - |
dc.subject.keywordPlus | PREVALENCE | - |
dc.subject.keywordAuthor | medical costs | - |
dc.subject.keywordAuthor | length of stay in hospital | - |
dc.subject.keywordAuthor | comorbidities | - |
dc.subject.keywordAuthor | COVID-19 | - |
dc.subject.keywordAuthor | Republic of Korea | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.